This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): ENA713D, ONO-2540, rivastigmine transdermal patch, Exelon TDS, Rivastach Patch (Japan)
Description: Exelon Patch (Rivastigmine tartrate) is a transdermal formulation of the reversible cholinesterase inhibitor Exelon. Inhibition of cholinesterases, which break down acetylcholine, leads to increased levels of acetylcholine in the brain, helping to boost cognition in Alzheimer's disease, where acetylcholine containing nerves are reduced.
Transdermal patches are designed to provide controlled, continuous delivery of drug through the skin. This maintains steady drug levels in the bloodstream, which may reduce side effects and consequently allow access to higher doses. In addition, patches may help caregivers to monitor treatment compliance because they provide visual reassurance that the medication has been taken.
Deal Structure: Historical sales for Exelon Patch are given as a percentage estimate of sales from Exelon. In 2012, Novartis began giving exact figures for Exelon Patch sales.
In December 2005, Novartis Pharma and Ono Pharmaceutical Co. agreed on the joint clinical development and marketing of rivastigmine transdermal patch for the treatment of Alzheimer's disease in Japan. Under the agreement, Novartis Pharma has granted the rights to Ono to co-develop and co-market this product in Japan.
Partners: Ono Pharmaceutical Company, Ltd.
Exelon Patch News
Pink Sheet Novartis To Submit Exelon Patch By Year-End
Additional information available to subscribers only: